Researcher Profile

Researcher Profile

Hong Zheng, MD, PhD

Hong Zheng, MD, PhD

Associate Professor, Department of Medicine
Division of Hematology and Oncology
Associate Professor, Department of Microbiology and Immunology
Scientific Program:Mechanisms of Carcinogenesis
Disease Teams:
Bone Marrow Transplantation
Immunotherapy
Leukemia and Lymphoma
hxz18@psu.edu

Research Interests

Dr. Hong Zheng's research focus is transplant immunology and developmental therapeutics for leukemia. Her study is dedicated to improve the understanding of the complex immune response involved in leukemia pathogenesis and allogeneic hematopoietic stem cell transplantation, and subsequently develop effective leukemia therapeutics.

Currently, she is involved in developing early-phase clinical studies testing the safety and efficacy of immunotherapy for leukemia. Her laboratory studies involve targeting T-cell inhibitory mechanisms as a strategy to improve anti-leukemia immunity.

  • T-Lymphocytes
  • Acute Myeloid Leukemia
  • Therapeutics
  • Leukemia
  • Neoplasms
  • Heat-Shock Proteins
  • Dendritic Cells
  • Immunoglobulin Domains
  • Immunotherapy
  • Graft vs Host Disease
  • Non-Small Cell Lung Carcinoma
  • Transplants

Clinical Trials

Blood and Bone Marrow Collection from Patients with Hematological Malignancies for Study of Anti-Tumor Immunity
Collection of Blood for Investigation and Characterization of Circulating Tumor Cells (CTCs) in Cancer Patients with Microdevices
bcr-abl PCR response to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia in Stable Chronic Phase.
Clofarabine followed by Fludarabine, Busulfan, Total-Body Irradiation and Hematopoietic Stem Cell Transplant with Post-Transplant Cyclophosphamide for Non-remission Acute Myeloid Leukemia
A Phase Ib/II Study of Venetoclax (ABT-199) in Combination with Liposomal Vincristine in Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) In Combination with Polatuzumab Vedotin in Patients with B-Cell Non-Hodgkin Lymphoma
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries with Multiple Myeloma: A Study to Develop Evidence of Effectiveness for the Centers for Medicare and Medicaid Services (CMS)
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
Difference in care and trends in outcomes of adolescent and young adult AML patients treated in pediatric and adult centers
NCI COVID-19 in Cancer Patients Study (N-CCaPS): A Longitudinal Natural History Study
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications
T-Cell Exhaustion in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia
Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation

Recent Publications

2021

Joshi, M, Holder, SL, Zhu, J, Zheng, H, Komanduri, S, Warrick, J, Yasin, H, Gajre, R, Jia, B, Drabick, J, Degraff, D & Zakharia, Y 2021, 'Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study', European Urology Focus. https://doi.org/10.1016/j.euf.2021.03.005
Tian, Y, Meng, L, Wang, Y, Li, B, Yu, H, Zhou, Y, Bui, T, Abraham, C, Li, A, Zhang, Y, Wang, J, Zhao, C, Mineishi, S, Gallucci, S, Porter, D, Hexner, E, Zheng, H, Zhang, Y, Hu, S & Zhang, Y 2021, 'Graft-versus-host disease depletes plasmacytoid dendritic cell progenitors to impair tolerance induction', Journal of Clinical Investigation, vol. 131, no. 1, e136774. https://doi.org/10.1172/JCI136774
Hou, JZ, Ye, JC, Pu, JJ, Liu, H, Ding, W, Zheng, H & Liu, D 2021, 'Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting', Journal of Hematology and Oncology, vol. 14, no. 1, 66. https://doi.org/10.1186/s13045-021-01077-3

2020

Zheng, H, Mineishi, S, Claxton, D, Zhu, J, Zhao, C, Jia, B, Ehmann, WC, Rybka, WB, Naik, S, Songdej, N, Drabick, JJ & Hohl, RJ 2021, 'A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia', American Journal of Hematology, vol. 96, no. 2, pp. E46-E50. https://doi.org/10.1002/ajh.26043
Wang, D, Du, J, Song, Y, Wang, B, Song, R, Hao, Y, Zeng, Y, Xiao, J, Zheng, H, Zeng, H, Zhao, H & Kong, Y 2020, 'CD70 contributes to age-associated T cell defects and overwhelming inflammatory responses', Aging, vol. 12, no. 12, pp. 12032-12050. https://doi.org/10.18632/aging.103368
Annageldiyev, C, Tan, SF, Thakur, S, Dhanyamraju, PK, Ramisetti, SR, Bhadauria, P, Schick, J, Zeng, Z, Sharma, V, Dunton, W, Dovat, S, Desai, D, Zheng, H, Feith, DJ, Loughran, TP, Amin, S, Sharma, AK, Claxton, D & Sharma, A 2020, 'The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia', Frontiers in Oncology, vol. 10, 393. https://doi.org/10.3389/fonc.2020.00393

2019

Rice, SJ, Liu, X, Zhang, J, Jia, B, Zheng, H & Belani, CP 2019, 'Advanced NSCLC patients with high IL-6 levels have altered peripheral T cell population and signaling', Lung Cancer, vol. 131, pp. 58-61. https://doi.org/10.1016/j.lungcan.2019.03.014
Kong, Y, Jia, B, Zhao, C, Claxton, DF, Sharma, A, Annageldiyev, C, Fotos, JS, Zeng, H, Paulson, RF, Prabhu, KS & Zheng, H 2019, 'Downregulation of CD73 associates with T cell exhaustion in AML patients', Journal of Hematology and Oncology, vol. 12, no. 1, 40. https://doi.org/10.1186/s13045-019-0728-3
Jia, B, Zhao, C, Rakszawski, KL, Claxton, DF, Christopher Ehmann, W, Rybka, WB, Mineishi, S, Wang, M, Shike, H, Bayerl, MG, Sivik, JM, Schell, TD, Drabick, JJ, Hohl, RJ & Zheng, H 2019, 'Eomes+T-betlow CD8+ T cells are functionally impaired and are associated with poor clinical outcome in patients with acute myeloid leukemia', Cancer Research, vol. 79, no. 7, pp. 1635-1645. https://doi.org/10.1158/0008-5472.CAN-18-3107
Zhao, C, Jia, B, Wang, M, Schell, TD, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Songdej, N, Sivik, JM, Hohl, RJ, Zeng, H & Zheng, H 2020, 'Multi-dimensional analysis identifies an immune signature predicting response to decitabine treatment in elderly patients with AML', British Journal of Haematology, vol. 188, no. 5, pp. 674-684. https://doi.org/10.1111/bjh.16228
Kong, Y, Tian, Y, Hao, Y, Chong, X, Xiao, J, Yang, D, Song, C, Han, J, Dai, G, Zhang, F, Zheng, H, Zhao, H & Zeng, H 2019, 'Two types of poor immunological responder showing distinct responses to long-term HAART', International Journal of Infectious Diseases, vol. 86, pp. 178-187. https://doi.org/10.1016/j.ijid.2019.07.037

2018

Song, Y, Wang, B, Song, R, Hao, Y, Wang, D, Li, Y, Jiang, Y, Xu, L, Ma, Y, Zheng, H, Kong, Y & Zeng, H 2018, ' T-cell Immunoglobulin and ITIM Domain Contributes to CD8 + T-cell Immunosenescence ', Aging cell, vol. 17, no. 2, e12716. https://doi.org/10.1111/acel.12716
Jia, B, Wang, L, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Rizvi, S, Shike, H, Bayerl, M, Schell, TD, Hohl, RJ & Zheng, H 2018, 'Bone marrow CD8 T cells express high frequency of PD-1 and exhibit reduced anti-leukemia response in newly diagnosed AML patients', Blood Cancer Journal, vol. 8, no. 3, 34. https://doi.org/10.1038/s41408-018-0069-4
Zhu, L, Liu, L, Zhang, Y, Pu, L, Liu, J, Li, X, Chen, Z, Hao, Y, Wang, B, Han, J, Li, G, Liang, S, Xiong, H, Zheng, H, Li, A, Xu, J & Zeng, H 2018, 'High Level of Neutrophil Extracellular Traps Correlates with Poor Prognosis of Severe Influenza A Infection', Journal of Infectious Diseases, vol. 217, no. 3, pp. 428-437. https://doi.org/10.1093/infdis/jix475
Wang, L, Jia, B, Claxton, DF, Ehmann, WC, Rybka, WB, Mineishi, S, Naik, S, Khawaja, MR, Sivik, J, Han, J, Hohl, RJ & Zheng, H 2018, 'VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML', OncoImmunology, vol. 7, no. 9, e1469594. https://doi.org/10.1080/2162402X.2018.1469594

2017

Hou, P, Wu, C, Wang, Y, Qi, R, Bhavanasi, D, Zuo, Z, Dos Santos, C, Chen, S, Chen, Y, Zheng, H, Wang, H, Perl, A, Guo, D & Huang, J 2017, 'A genome-wide CRISPR screen identifies genes critical for resistance to FLT3 inhibitor AC220', Cancer Research, vol. 77, no. 16, pp. 4402-4413. https://doi.org/10.1158/0008-5472.CAN-16-1627
Zhu, L, Kong, Y, Zhang, J, Claxton, DF, Ehmann, WC, Rybka, WB, Palmisiano, ND, Wang, M, Jia, B, Bayerl, M, Schell, TD, Hohl, RJ, Zeng, H & Zheng, H 2017, 'Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia', Journal of Hematology and Oncology, vol. 10, no. 1, 124. https://doi.org/10.1186/s13045-017-0486-z
Jiang, P, Li, S, Lai, J, Zheng, H, Lin, C, Shi, P & Wang, Y 2017, 'Nanoparticle-Programmed Surface for Drug Release and Cell Regulation via Reversible Hybridization Reaction', ACS Applied Materials and Interfaces, vol. 9, no. 5, pp. 4467-4474. https://doi.org/10.1021/acsami.6b14355

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)